GRAIL Galleri
Multi-cancer early detection from a single blood draw
2016
Menlo Park, USA
$949
grail.com
Overview
Galleri is a multi-cancer early detection test that screens for 50+ cancer types from a single blood draw, many of which have no standard screening today. It detects cancer signals in cell-free DNA and predicts the cancer signal origin.
Why It's Notable
Detected cancers with no other screening method. NHS launched world's largest trial with 140,000 participants.
How It Works
A standard blood draw is analyzed for cell-free DNA (cfDNA) methylation patterns. Machine learning identifies cancer-specific methylation signatures and predicts the tissue of origin with 89% accuracy for signal-detected cancers.
Key Features
Team & Background
Spun out of Illumina. $2B+ in funding from Jeff Bezos, Bill Gates, and others.
Disclaimer: This information is for educational purposes only. Health.AI does not endorse, sell, or receive compensation from any listed product. Always consult your healthcare provider before using any health technology. Product claims are based on manufacturer data and published research at the time of listing.